There are contraindications! Be sure to consult your doctor before taking any medication!
Nucoxia-MR consists of Etoricoxib, Thiocolchicoside.
Etoricoxib - Nucoxia-MR (Etoricoxib) is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Nucoxia-MR (Etoricoxib) selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2). This reduces the generation of prostaglandins (PGs) from arachidonic acid.
Indication: For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.
Nucoxia-MR (Etoricoxib) is a COX-2 selective inhibitor (approximately 106 times more selective for COX-2 inhibition over COX-1). Currently it is approved in more than 60 countries worldwide but not in the US, where the Food and Drug Administration (FDA) require additional safety and efficacy data for Nucoxia-MR (Etoricoxib) before it will issue approval.
Pharmaceutical active ingredients containing related brand and generic drugs, medications or other health care products: